BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/18/2025 8:11:49 AM | Browse: 104 | Download: 340
 |
Received |
|
2024-08-07 02:11 |
|
Peer-Review Started |
|
2024-08-07 02:11 |
|
First Decision by Editorial Office Director |
|
2024-10-11 09:58 |
|
Return for Revision |
|
2024-10-11 09:58 |
|
Revised |
|
2024-10-23 03:46 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-11-05 02:40 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-11-05 07:34 |
|
Articles in Press |
|
2024-11-05 07:34 |
|
Edit the Manuscript by Language Editor |
|
2024-11-13 03:40 |
|
Typeset the Manuscript |
|
2024-11-19 03:47 |
|
Publish the Manuscript Online |
|
2025-01-18 08:11 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Immunology |
| Manuscript Type |
Editorial |
| Article Title |
Nucleotide-binding domain, leucine-rich repeat, and pyrin domain-containing protein 3 inflammasome: From action mechanism to therapeutic target in clinical trials
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Chun-Ye Zhang, Shuai Liu, Yu-Xiang Sui and Ming Yang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ming Yang, Assistant Professor, PhD, Department of Surgery, University of Connecticut, School of Medicine, 263 Farmington Avenue, Farmington, CT 06030, United States. minyang@uchc.edu |
| Key Words |
Clinical trial; Immunotherapy; Cancer; Inflammation; Metabolic disease; Nucleotide-binding domain, leucine-rich repeat, and pyrin domain-containing protein 3 |
| Core Tip |
The nucleotide-binding domain, leucine-rich repeat, and pyrin domain-containing protein 3 (NLRP3) inflammasome plays a pivotal role in many diseases such as inflammatory diseases, metabolic disorders, and neurodegenerative diseases. The investigation of NLRP3 as a therapeutic target is involved in many preclinical studies and clinical trials. Among these studies, NLRP3 inhibitors and downstream interleukin-1 inhibitors attract wide-spectrum attention. In addition, NLRP3 activation also impacts cancer development and immunotherapy, serving as a potential therapeutic target for cancer treatment. |
| Publish Date |
2025-01-18 08:11 |
| Citation |
Zhang CY, Liu S, Sui YX, Yang M. Nucleotide-binding domain, leucine-rich repeat, and pyrin domain-containing protein 3 inflammasome: From action mechanism to therapeutic target in clinical trials. World J Gastrointest Oncol 2025; 17(2): 100094 |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i2/100094.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i2.100094 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
